Felocell CVR
Introduction

Company name: Pfizer Limited
Address: Ramsgate Road
Sandwich
Kent CT13 9NJ
Telephone: 0845 300 8034 (Out of hours: 01304 616161)
Fax: 01737 332521
Email: UKVetLine@pfizer.com
Website: www.only4vets.co.uk
Presentation
A freeze-dried fraction containing live attenuated feline enteritis (panleucopaenia) virus (FPV), Snow Leopard strain ≥ 103.0 CCID50, live attenuated feline rhinotracheitis virus (FVR), strain FVRm ≥ 105.0 CCID50 and live attenuated feline calicivirus (FCV), strain F9 ≥ 105.5 CCID50, supplied with a vial of water for injection for reconstitution.
Uses
For the active immunisation of healthy cats to reduce mortality and clinical signs of disease caused by feline enteritis (panleucopaenia) virus, to reduce clinical signs of disease caused by feline rhinotracheitis virus and to prevent clinical signs of disease and reduce infection caused by feline calicivirus.
Onset of immunity occurs by approximately 3 weeks after the last dose of the Basic Vaccination Scheme.
The duration of immunity is at least 12 months.
Dosage and administration
Reconstitute the freeze-dried vaccine aseptically with the entire contents of the diluent provided. Shake and immediately inject the contents of the vial subcutaneously, 1 ml per dose.
Basic Vaccination Scheme:
In cats aged nine weeks and over, two injections of Felocell CVR, 3 to 4 weeks apart will stimulate full active immunity.
Re-vaccination:
A single 1 ml dose is required on an annual basis.
If simultaneous immunisation against feline leukaemia virus (FeLV) is required, Felocell CVR can be reconstituted with Leukocell 2 (inactivated, adjuvanted sub-unit FeLV vaccine) in place of the diluent, using the reconstitution method described above. Once mixed, the vaccines should be injected immediately via the subcutaneous route.
Do not use chemically sterilised syringes or needles, as these might affect the response of the vaccine.
Contra-indications, warnings, etc
Do not vaccinate unhealthy or pregnant animals.
On rare occasions, transient increases in rectal temperature, transient lameness and transient lethargy may be observed as well as soft painless swellings (<1cm average) may occur in the first 24 hours after vaccination, which may be evident as painless hard nodules for up to 21 days after dosing.
On very rare occasions, an anaphylactic reaction may occur which may require appropriate symptomatic treatment (e.g. adrenaline).
No reactions other than those listed above have been observed after an accidental overdose.
The feline panleucopaenia virus and the feline calicivirus vaccinal strains may be shed from vaccinated animals for a number of days following vaccination. However, due to the low pathogenicity of these strains it is not necessary to keep vaccinated animals separated from non-vaccinated animals.
Moderate to high levels of maternally derived antibodies (MDA) may interfere with the response to vaccination.
When Felocell CVR and Leukocell 2 are administered simultaneously, incidence of local reactions may be increased.
Operator warning:
In case of accidental self-injection, wash the area immediately with water. If symptoms develop, seek medical attention showing a copy of the product literature.
Pharmaceutical precautions
Store and transport between 2°C and 8°C. Do not freeze.
Do not mix with any other vaccine or immunological product except the diluent provided or Leukocell 2 (inactivated, adjuvanted sub-unit FeLV vaccine).
No information is available on the safety and efficacy from the concurrent administration of this vaccine with any other except Leukocell 2. It is therefore recommended that no other vaccine than this should be administered within 14 days before or after vaccination with Felocell CVR.
Dispose of waste materials by boiling, incineration or immersion in an appropriate disinfectant in accordance with national requirements.
For animal treatment only.
Keep out of reach of children.
Legal category
POM-V
Packaging Quantities
Packs containing 25 doses of Felocell CVR. Packs of disposable syringes with needles are also available.
Marketing authorisation number
Vm 00057/4113.